VIDEO: Inotuzumab ozogamicin shows ‘encouraging’ results in high-risk ALL population
Inotuzumab ozogamicin was well tolerated among patients with acute lymphoblastic leukemia who had undergone allogenic transplantation in a small study.
The phase 1 findings, presented at the ASH Annual Meeting and Exposition, showed that many patients who received inotuzumab ozogamicin (Besponsa, Pfizer) were still relapse-free at 1-year posttransplant.
These results were “very encouraging for a high-risk population,” Anjali Advani, MD, director of the inpatient leukemia program at Cleveland Clinic’s Taussig Cancer Institute, said in a video interview.
“Longer follow-up is needed, but in this population that’s high risk, you would typically expect a high risk of relapse within the first year,” Advani told Healio. “I think this will be really an exciting field to watch going forward.”
Collapse
Metheny III L, et al. Abstract 2899. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.
Read more about